Open · HT942526ALSRPTIA · CFDA 12.420 · Discretionary

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Open
Status
48d
Days left
12
Expected awards

The verdict

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award is an open discretionary opportunity from Defense Health Agency Contracting Activity - DHACA, offering Varies by applicant across 12 expected awards. Applications close in 48 days.

Varies
award range
Open
48 days left
12
expected awards
12.420
CFDA program

Opportunity snapshot. This Grants.gov announcement - DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award - is cataloged under number HT942526ALSRPTIA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as open, first posted on May 4, 2026 and last updated on May 6, 2026. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. The agency has projected $10.1 million in total estimated funding for this announcement. It expects to issue 12 awards. If the agency funds the expected 12 awards from the $10.1 million estimated pool, the average award works out to roughly $840,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. Applications close on September 30, 2026 - roughly 48 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Varies by applicant

Close Date

September 30, 2026

Posted

May 4, 2026

Est. Total Funding

$10,080,000

Expected Awards

12

Instrument

Grant

Description

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Eligibility

Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

Key Dates

Posted May 4, 2026
Close Date September 30, 2026
Archive Date October 30, 2026
Last Updated May 6, 2026

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award", offered by Defense Health Agency Contracting Activity - DHACA. It is associated with CFDA program 12.420. Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic later...
Is this opportunity still open?
Yes, this opportunity is currently open for applications. The closing date is September 30, 2026.
How much funding is available?
The award range for this opportunity is Varies by applicant. Total estimated funding: $10,080,000. Expected number of awards: 12.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants